Mineralys Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Mineralys Therapeutics (NASDAQ: MLYS), a clinical-stage biopharmaceutical company, will participate in the Goldman Sachs 45th Annual Global Healthcare Conference in Miami, FL from June 10-13, 2024. The company's management will engage in a fireside chat on June 11, 2024, at 4:00 pm EDT. The discussion will be webcast live and accessible through the Investor Relations section on the Mineralys website, with a replay available for 90 days.
- Participation in the Goldman Sachs 45th Annual Global Healthcare Conference can enhance Mineralys' visibility and credibility in the biopharmaceutical sector.
- The fireside chat provides a platform to communicate the company's progress and future plans to potential investors and stakeholders.
- Webcasting the event live and offering a replay for 90 days increases accessibility and the potential to reach a wider audience.
- There are no new clinical data or financial updates provided in the press release, which may be seen as a lack of substantial news.
- Participation in conferences, while beneficial for visibility, does not directly impact the company's short-term financial performance.
- The press release does not mention any breakthroughs or advancements, which could be perceived as stagnation by investors.
RADNOR, Pa., June 03, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference, being held in Miami, FL on June 10-13, 2024.
| Goldman Sachs 45th Annual Global Healthcare Conference: | |
| Date: | Tuesday, June 11, 2024 |
| Time: | 4:00pm EDT |
| Format: | Fireside Chat |
| Webcast Link | |
A live webcast of the fireside chat can be accessed under “News and Events” on the Investor Relations section of the Mineralys website at www.mineralystx.com. A replay of the fireside chat will be available on the Company’s website for approximately 90 days.
About Mineralys Therapeutics
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, CKD and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys Therapeutics is developing for cardiorenal conditions affected by dysregulated aldosterone, including hypertension and CKD. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn and Twitter.
Contact:
Investor Relations
investorrelations@mineralystx.com
Media Relations
Tom Weible
Elixir Health Public Relations
Phone: (1) 515-707-9678
Email: tweible@elixirhealthpr.com
FAQ
What is Mineralys Therapeutics' stock symbol?
When is Mineralys Therapeutics participating in the Goldman Sachs 45th Annual Global Healthcare Conference?
What type of event will Mineralys Therapeutics participate in at the Goldman Sachs conference?
When will the fireside chat featuring Mineralys Therapeutics take place?
How can I access the live webcast of Mineralys Therapeutics' fireside chat?
How long will the replay of the fireside chat be available on Mineralys Therapeutics' website?
